Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Rein Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Rein Therapeutics, Inc.

RNTX

Rein Therapeutics, Inc.

About Rein Therapeutics, Inc.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for orphan pulmonary and fibrosis conditions. Its lead candidates, LTI-03 and LTI-01, target idiopathic pulmonary fibrosis and loculated pleural effusion, respectively. With a significant market opportunity and Orphan Drug Designation for both products, Rein aims to address unmet medical needs while pursuing collaborations to enhance development and commercialization efforts.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Rein Therapeutics, Inc.

1
1
Rein Therapeutics, Inc. Rein Therapeutics Reports $5.8 Million Net Loss in Q1 2026, Focuses on LTI-03 Development

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Rein Therapeutics, Inc. Rein Therapeutics Reports $49.9M Net Loss and Progress on LTI-03 in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Rein Therapeutics, Inc. Rein Therapeutics Reports Q3 2025 Financial Results with $5.6M Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Rein Therapeutics, Inc. Rein Therapeutics Reports Q2 2025 Financial Results with $6.8M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Rein Therapeutics, Inc. Rein Therapeutics Reports $5.5 Million Net Loss in Q1 2025, Focuses on Fibrotic Disease Therapies

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Rein Therapeutics, Inc. Rein Therapeutics Reports $62.88 Million Net Loss for 2024, Plans for Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Rein Therapeutics, Inc. Aileron Therapeutics Reports Financial Results, Raises Doubts About Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments